WO2016103005A1 - Method of culturing segmented filamentous bacteria in vitro - Google Patents

Method of culturing segmented filamentous bacteria in vitro Download PDF

Info

Publication number
WO2016103005A1
WO2016103005A1 PCT/IB2014/067285 IB2014067285W WO2016103005A1 WO 2016103005 A1 WO2016103005 A1 WO 2016103005A1 IB 2014067285 W IB2014067285 W IB 2014067285W WO 2016103005 A1 WO2016103005 A1 WO 2016103005A1
Authority
WO
WIPO (PCT)
Prior art keywords
sfb
strain
culturing
cell
eukaryotic host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/067285
Other languages
English (en)
French (fr)
Inventor
Gérard EBERL
David Bikard
Pamela SCHNUPF
Nadine CERF BENSUSSAN
Valérie GABORIAU-ROUTHIAU
Philippe Sansonetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Priority to PCT/IB2014/067285 priority Critical patent/WO2016103005A1/en
Priority to EP15830866.8A priority patent/EP3237602B1/en
Priority to AU2015370419A priority patent/AU2015370419B2/en
Priority to CA2971933A priority patent/CA2971933C/en
Priority to JP2017534355A priority patent/JP6963999B2/ja
Priority to CN201580072958.4A priority patent/CN107429222B/zh
Priority to PCT/IB2015/059948 priority patent/WO2016103217A1/en
Priority to US15/538,184 priority patent/US10435665B2/en
Publication of WO2016103005A1 publication Critical patent/WO2016103005A1/en
Anticipated expiration legal-status Critical
Priority to US16/548,280 priority patent/US11725183B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/23—Gastro-intestinal tract cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to an in vitro method for growing segmented filamentous bacteria (SFB).
  • the present invention also relates to methods for genetically modifying a SFB strain.
  • Segmented filamentous bacteria or Candidatus arthromitus or Candidates savagella or Arthromitus immunis or Arthromitus muris are gram-positive anaerobic, clostridia-related, spore-forming commensals found in the gut (distal illeum) of many vertebrate species, including mouse, rat, rabbit, birds (e.g., chicken), fish, amphibian and probably humans (Klaasen et al, 1992; Yin et al, 2012).
  • the size of the filament is comprised between 0.5 and 1000 ⁇ in length.
  • SFB produce intracellular offsprings (Schnupf et al , 2013; Ericsson et. al, 2014 for review). Intracellular offsprings once formed are unicellular until they start to filament and become bicellular, then tricellular.
  • SFB have garnered much interest because of their unique ability to educate the gut immune system and to induce a healthy state of physiological inflammation (Schnupf et al, 2013; Ivanov et al, 2009).
  • SFB colonization leads to the maturation of the gut mucosal lymphoid tissue, induces a strong and broad IgA response, stimulates the T-cell compartment, upregulates intestinal innate defence mediators, and induce a striking increase in the small-intestinal Thl7 responses (Schnupf et al, 2013; Ivanov et al, 2009; Gaboriau- Routhiau et al, 2009).
  • SFB colonization exerts an adjuvant effect on systemic responses and can thus exacerbate pathologies in mouse models of encephalitis and arthritis, while protecting genetically predisposed mice against the development of type I diabetes (Lee et al, 201 1; Wu et al, 2010; Chappert et al, 2013; Kriegel et al, 201 1 ; Yurkovetskiy et al, 2013).
  • segmented filamentous bacterium intimately attaches to absorptive epithelial cells in the ileum and cells overlying Peyer's patches (Jepson et al, 1993; Chase et al, 1976). This colonization does not result in pathology; rather, it protects the host from pathogens (Ivanov et al. , 2009).
  • the inventors have grown mouse SFB outside their host in a segmented filamentous bacterium-host cell co-culturing system.
  • the inventors have shown that in this system, single-celled SFB isolated from monocolonized mice undergo filamentation, segmentation, and differentiation to release viable infectious particles, the unicellular intracellular offspring, which can colonize mice to induce signature immune responses.
  • the inventors have also observed in this co-culturing system the formation of SFB spores.
  • intracellular offspring can attach to mouse and human host cells and recruit actin. Further, SFB can potently stimulate the upregulation of host innate defence genes, inflammatory cytokines, and chemokines.
  • the present invention provides an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an 0 2 level inferior to 5%, preferably inferior to 4%, in a rich tissue culture liquid medium containing bacterial medium components including iron.
  • segmented filamentous bacterium strain refers to a Candidatus arthromitus or Candidatus savagella or Arthromitus immunis or Arthromitus muris strain, preferably a Arthromitus muris strain.
  • the method comprises the steps of:
  • step b) immerging the eukaryotic host cells grown in step a) in a eukaryotic host cell-
  • step b) challenging the cell culture of step b) with a SFB strain, preferably an intracellular SFB offspring;
  • the eukaryotic host cell can be any vertebrate cell, preferably any mammalian cell, more preferably any human or murine cell (e.g., a mouse cell).
  • the eukaryotic host cell is an adherent cell in vitro.
  • this adherent cell is able to differentiate and hence fares well under confluent conditions for extended periods of time in vitro.
  • the eukaryotic host cell is an epithelial cell.
  • the eukaryotic host cell is a cell from the gastrointestinal tract, such as the colon or small intestine.
  • the eukaryotic host cell is a cancer cell, preferably a carcinoma cell, more preferably an adenocarcinoma cell.
  • the eukaryotic host cell is a mammalian gastrointestinal epithelial adherent cell or a mammalian adherent cancer cell, in particular a human or mouse colon epithelial or small intestine cell or a human or mouse adenocarcinoma cell.
  • the eukaryotic host cell is selected from the group consisting of the human Caco-2, TC7 (which is a subclone of Caco-2) or HeLa cell lines or mouse mICcl2 or CMT93 cell lines, preferably the human Caco-2 or TC7 cell line.
  • the eukaryotic host cell is grown at an 0 2 level comprised between 0% (anaerobic conditions) and 5%, preferably between 0.5 and 3%, more preferably between 1 and 2.5%.
  • the humidity and temperature conditions for growing the eukaryotic host cell can be determined by routine tests by a person skilled in the art.
  • the composition of the eukaryotic host cell culture medium can be determined by routine tests by a person skilled in the art.
  • the culture medium comprises Dulbecco's Modified Eagle Medium (DMEM) or Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) advanced medium, inactivated fetal calf serum (FCS) and amino acids.
  • DMEM Dulbecco's Modified Eagle Medium
  • DMEM/F12 Nutrient Mixture F-12
  • FCS inactivated fetal calf serum
  • the eukaryotic host cell is grown until a cell confluence of at least 20%, and by order of increasing preference of at least 25%, 30%, 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, and more preferably of 100%, is obtained.
  • the eukaryotic host cell is grown until a cell monolayer is obtained.
  • the eukaryotic host cells grown in step a) are plated on a plate, preferably on a tissue culture well or transwell, more preferably on a tissue culture transwell, prior to step b).
  • step b With regard to step b :
  • the eukaryotic host cell-SFB liquid culture medium is a medium suitable for culturing both the eukaryotic host cell and the SFB strain.
  • said liquid culture medium is a rich tissue culture medium (e.g.,
  • DMEM/F12 advanced medium containing bacterial medium components including iron.
  • Said liquid culture medium can comprise brain-heart infusion and a yeast/peptone/casein amino-acid mixture. These bacterial medium complements are well known in the art.
  • Iron can be in the ferrous form (Fe 2+ state) and/or ferric (Fe 3+ state).
  • iron can be in the form of Fe 2+ /Fe 3+ , 3xFe 2+ , 3xFe 2+ or hemin, preferably Fe 2+ /Fe 3+ , 3xFe 2+ or 3xFe 2+ .
  • iron concentration is comprised between 0.015 and 0.05 mM, preferably between 0.02 and 0.04 mM.
  • said liquid culture medium comprises a medium for culturing the eukaryotic host cell, such as DMEM/F12 advanced medium, supplemented with fetal calf serum, non-essential amino acids (such as GlutamaxTM), 4-(2-hydroxyethyl)-l- piperazineethanesulfonic acid (HEPES), brain-heart infusion, a yeast/peptone/casein amino- acid mixture and iron.
  • DMEM/F12 advanced medium supplemented with fetal calf serum, non-essential amino acids (such as GlutamaxTM), 4-(2-hydroxyethyl)-l- piperazineethanesulfonic acid (HEPES), brain-heart infusion, a yeast/peptone/casein amino- acid mixture and iron.
  • said liquid culture medium further comprises sugars, retinoic acid and/or nucleotides.
  • the SFB strain can be a wild-type strain or a genetically modified strain.
  • a genetically modified SFB strain can be obtained from a wild-type SFB strain by transformation, transduction or conjugation.
  • the SFB strain can be in the form of a filament or an intracellular offspring.
  • the SFB strain can be isolated from a subject, in particular a mammal, such as a human or a mouse (e.g., a SFB monoassociated mouse). Methods for isolating a SFB strain from a mammal are known in the art (Lecuyer et al, 2014).
  • a SFB filament can be isolated by the following method: the ileal, caecal, and/or colonic contents from a subject is collected and the individual filament is captured using an inverted microscope and a micropipette attached to a micromanipulator.
  • An intracellular SFB offspring can be isolated under anaerobic conditions by the following method: the ileal, caecal, and/or colonic contents from a subject is collected, filtered through a 100- ⁇ mesh, separated from other faecal matter using a density gradient column and passed through a 5- ⁇ filter to obtain a pure culture of unicellular intracellular offspring (average 0.7 ⁇ ). SFB filaments can also be collected on 5 ⁇ filters following this method.
  • challenging refers to the addition of a bacterium to an eukaryotic host cell regardless of whether this bacterium interacts (attaches/invades) or not the host cell.
  • the SFB strain is closely contacted with the eukaryotic host cell, preferably is in direct contact with the eukaryotic host cell.
  • the term "closely contacted” refers to a co-culture of a eukaryotic host cell and a SFB strain wherein the distance between said eukaryotic host cell and said SFB strain is inferior or equal to 2 cm.
  • the co-culture of the eukaryotic host cell and the SFB is performed at an 0 2 level comprised between 0% (anaerobic conditions) and 5%, preferably between 0.5 and 3%, more preferably between 1 and 2.5%.
  • the humidity and temperature conditions for co-culturing the live eukaryotic host cell and the SFB strain can be determined by routine tests by a person skilled in the art.
  • the co-culture can be performed for 1, 2, 3, 4, 5 or 6 days.
  • the co-culture can also be performed until the SFB strain undergoes filamentation, segmentation, differentiation to release intracellular offsprings or spores.
  • Conditions to induce spore formation advantageously include adding a stress such as oxidative stress or short times of antibiotics (Davis and Savage, 1976).
  • the cultured SFB strain can be recovered in a form of a filament, an intracellular offspring or a spore.
  • a SFB filament can be recovered using an inverted microscope and a micropipette attached to a micromanipulator.
  • a SFB intracellular offspring can be recovered from a filament by filtration through a 5- ⁇ filter. SFB filaments can be collected on 5 ⁇ filters.
  • a SFB spore (that is a bacterial spore) can be recovered by a method well known in the art, such as the methods disclosed in International Application WO 2014/121298.
  • the present invention also provides the Arthromitus muris strain deposited by the Applicant, according to the Budapest Treaty, at CNCM (Collection Nationale de Cultures de Microorganismes, 25 rue du Dondel Roux, Paris) on December 23, 2014, under the accession number CNCM 1-4932.
  • the present invention also provides a method for genetically modifying a segmented filamentous bacterium strain by conjugation, comprising the steps of:
  • step ii) co-culturing the genetically modified E. coli strain obtained in step i) together with the SFB strain to be targeted for genetic modification according to the in vitro method of culturing of the invention, wherein:
  • step c) of said method of culturing of the invention the cell culture of step b) is challenged with both the SFB strain to be targeted for genetic modification, preferably an intracellular SFB offspring, and said genetically modified E. coli strain ; and
  • step d) of said method of culturing of the invention the live eukaryotic host cell, the SFB strain and the genetically modified E. coli strain are co-cultured in the liquid culture medium at an 0 2 level inferior to 5%;
  • the recombinant shuttle vector DNA can be a recombinant Clostridial shuttle vector DNA comprising a DNA sequence of interest and capable of replicating both in an E. coli strain and in a Clostridia strain.
  • the construction of such a vector is known in the art (Heap et al, 2009).
  • the DNA sequence of interest can be under the control of a constitutive SFB, such as ribosomal, promoter for cytosolic expression or fused to a nucleotide sequence encoding a secreted lipoprotein for surface expression.
  • a constitutive SFB such as ribosomal, promoter for cytosolic expression or fused to a nucleotide sequence encoding a secreted lipoprotein for surface expression.
  • the recombinant shuttle vector DNA can comprise different selectable antibiotic markers.
  • the DNA sequence of interest can be a DNA sequence encoding an antigen of interest.
  • the antigen of interest can be IpaB or IpaD from Shigella flexneri.
  • the E. coli strain can be a negatively-selectable auxotrophic E. coli strain (Danchin,
  • the E.coli strain requires diaminopimelic acid to grow.
  • Such a strain can be selected against diaminopimelic acid in a rich culture medium.
  • the genetic modification of the E. coli strain can be carried out by electroporation, transduction, heat shock transformation or protoplast fusion.
  • step ii) allows transferring the said shuttle vector DNA from the E. coli strain to the SFB by conjugation.
  • the cell culture of step b) is challenged first with the SFB strain to be targeted for genetic modification, and then with said genetically modified E. coli strain after there is outgrowth of the SFB strain.
  • the present invention also provides a method for genetically modifying a segmented filamentous bacterium strain by electroporation, comprising the steps of:
  • step ii) mixing the SFB strain recovered in step i) with a purified plasmid to be transformed, preferably in glycerol/H 2 0 (e.g., 10% glycerol/H 2 0);
  • step i) of this method the SFB strain can be cultured for 2-4 days on TC7 cells.
  • the SFB strain can be recovered by collecting the SFB cell and putting it on ice under 0 2 level comprised between 0% (anaerobic condition) and 5%, preferably between 0.5 and 3%, more preferably between 1 and 2.5%.
  • the electric field is advantageously comprised between 6 kV.cm “1 and 30 kV.cm “1 , preferably between 6.5 kV.cm “1 and 25 kV.cm “1 .
  • the purified plasmid can be designed for use in Clostridia species (Heap et al, 2009).
  • the present invention also provides a method for genetically modifying a segmented filamentous bacterium strain by chemical transformation, comprising the steps of:
  • step ii) mixing the SFB strain recovered in step i) with a purified plasmid to be transformed, preferably in glycerol/calcium chloride (e.g., 10% glycerol/0.1M calcium chloride);
  • glycerol/calcium chloride e.g., 10% glycerol/0.1M calcium chloride
  • the SFB strain can be cultured for 2-4 days on TC7 cells.
  • the SFB strain can be recovered by collecting the SFB cell and putting it on ice under 0 2 level comprised between 0% (anaerobic condition) and 5%, preferably between 0.5 and 3%, more preferably between 1 and 2.5%.
  • step iii) the SFB strain and the purified plasmid can be incubated for 15 to
  • step iv) the heat shocked is advantageously applied at 41-43 °C, preferably at 42°C for 15 to 45 seconds, preferably 30 seconds.
  • a live genetically modified SFB strain can be used as an antigen delivery vehicle, either as filament, intracellular offspring or spore, preferably as a spore, after oral ingestion or parenteral administration to a subject, preferably a mammal.
  • the present invention also provides an isolated genetically modified SFB strain expressing an antigen of interest (e.g., IpaB or IpaD from Shigella flexneri), preferably secreting said antigen or exposing said antigen on bacterium's surface.
  • an antigen of interest e.g., IpaB or IpaD from Shigella flexneri
  • an antigen of interest refers to an antigen derived from a microorganism or a cell (e.g., tumor cell) against which one intends to elicit an immune response in a subject.
  • the genetically modified SFB strain can be obtained by transformation, transduction or conjugation as described above, preferably by a method for genetically modifying a segmented filamentous bacterium strain according to the invention.
  • the present invention also provides a live genetically modified SFB strain expressing an antigen of interest as defined above for use as a medicament, in particular for use in preventing or treating a disease caused by a microorganism from which said antigen derives, or a cancer.
  • Said SFB strain can be in the form of a filament, an intracellular offspring or a spore, preferably a spore.
  • the present invention also provides a therapeutic immunogenic (or vaccine) composition comprising a live genetically modified SFB strain expressing an antigen of interest as defined above.
  • Said SFB strain can be in the form of a filament, an intracellular offspring or a spore, preferably a spore.
  • immunogenic composition and “vaccine composition” are used interchangeably herein.
  • the present invention also provides an immunogenic composition as described above for use in preventing or treating a disease caused by a microorganism from which said antigen derives or a cancer.
  • the genetically modified SFB strain expressing an antigen of interest and the immunogenic composition comprising the said genetically modified SFB strain according to the present invention are particularly suitable for eliciting in a subject antibodies directed to said antigen.
  • said immunogenic composition comprises a pharmaceutically acceptable carrier.
  • a "pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field.
  • the genetically modified SFB strain expressing an antigen of interest and the immunogenic composition comprising the said genetically modified SFB strain according to the present invention are administered to a mammal subject, preferably a human, in an amount sufficient to prevent or attenuate the severity, extent of duration of the infection by the microorganism from which said antigen derives or a cancer.
  • the therapeutically effective amount varies depending on the subject being treated, the age and general condition of the subject being treated, the capacity of the subject's immune response to synthesize antibodies, the degree of protection desired, the severity of the condition to be treated, and its mode of administration, among other factors.
  • An appropriate effective amount can be readily determined by one of skill in the art.
  • a therapeutically effective amount will fall in a relatively broad range that can be determined through routine trials.
  • the subject may receive one or two booster injections at an appropriate interval determined by one of skill in the art.
  • the immunogenic composition is prepared as an injectable form (either a liquid solution or suspension) or as a solid form suitable for solution or suspension in a liquid carrier prior to injection.
  • the immunogenic composition may be administered parenterally or by mucosal routes, preferably orally.
  • the present invention also provides the use of a genetically modified SFB strain expressing an antigen of interest or an immunogenic composition as defined above for the manufacture of a medicament, preferably of a preventive or therapeutic vaccine againt a microorganism from which said antigen derives in a subject or a cancer.
  • the present invention also provides a method for preventing and/or treating a infection caused by a microorganism from which said antigen derives or a cancer, comprising administering to a subject in need thereof a genetically modified SFB strain expressing an antigen of interest or an immunogenic composition as defined above, in an amount effective to inhibit said microorganism infection of susceptible cells so as to thereby prevent or treat the infection or to inhibit the growth of cancer cells so as to thereby prevent or treat cancer.
  • treating includes the administration of a genetically modified SFB strain expressing an antigen of interest or an immunogenic composition as defined above to a patient who has an infection, a symptom of infection or a cancer, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the infection and/or the symptoms of the infection, or the cancer.
  • preventing means that the progression of an infection is reduced and/or eliminated, or that the onset of an infection or cancer is delayed or eliminated.
  • the present invention also provides the use of a SFB strain obtainable by the in vitro method of culturing of the invention, as a probiotic.
  • Said SFB strain can be alive or dead, preferably alive.
  • Said SFB strain can be in the form of a filament, an intracellular offspring or a spore, preferably a spore.
  • the present invention also provides a food product (e.g., dairy product) comprising a SFB strain obtainable by the in vitro method of culturing of the invention.
  • a food product e.g., dairy product
  • a SFB strain obtainable by the in vitro method of culturing of the invention.
  • Said SFB strain can be alive or dead, preferably alive.
  • Said SFB strain can be in the form of a filament, an intracellular offspring or a spore, preferably a spore.
  • the invention further comprises other features which will emerge from the following description, which refers to examples illustrating the present invention, as well as to the appended figures.
  • Figure 1 Growth and growth requirements of SFB in vitro, a, Gram stain and length of SFB before and after 5- ⁇ filtration; b, qPCR of SFB growth on host cells at the indicated conditions; c, SEM images of 4-day-old SFB filaments grown anaerobically on
  • FIG. 2 Differentiation of SFB from filaments to intracellular offspring during in vitro growth.
  • A Schematic representation of an SFB filament highlighting stages of its growth and differentiation. Gram stain of SFB after 4 days of growth on B, TC7 cells incubated at the indicated condition, and C, TC7 cells grown on transwells in low oxygen. Analysis of SFB grown on mICcl2 cells (D-G) and TC7 cells (H) on transwells at 1-2.5% 02: D, qPCR quantification (mean ⁇ s.d. of triplicates); E, length of individual SFBs; F, Gram stain; and G, segment length analysis of representative 2-day-old SFB filaments. H, SEM of SFB after 4 days of growth. B-H, Representative images and values from one of three experiments performed in triplicate with (D) means ⁇ s.d.
  • Figure 3 Viability, colonization, and immunostimulatory potential of in vitro- grown SFB.
  • a SFB length after growth on TC7 cells on transwells;
  • b quantification and c, Gram stain of SFB growth on TC7 cells on transwells before and after a 3-day sub-culturing of the 5- ⁇ filtrate;
  • d-k analysis of germ-free C57BL/6 mice gavaged with either filament/intracellular offspring mix, intracellular offspring, or faeces of SFB-monoassociated mice (SFBFvo);
  • d quantification of ileum-associated SFB;
  • e k
  • h faecal secretory IgA quantification by ELISA.
  • FIG. 4 SFB-host cell interaction and host response. SEM of SFB attached to subconfluent (A) and confluent (B) mICcl2 cells after 2 days of intracellular offspring challenge.
  • C Merge (M) of 4',6-diamidino-2-phenylindole (DAPI) (D) and actin (A) stain of mICcl2 cells challenged with intracellular offspring for 2 days showing confocal slices (s) and Z-projections.
  • D SEM of 3-day-old SFB filament attached to TC7 cells.
  • FIG. 5 Intestinal colonization of in wYro-grown SFB and host response, a, b, qPCR quantification (a) and SEM (b) of in vi ' ro-grown SFB used for gavage. c, qPCR quantification of SFB in faecal samples, d, SEM of SFB attachment in vivo at 25 days after gavage of C57BL/6 mice with SFBVivo or SFBVitro. e, SEM of 21-day SFBcolonized germ- free C3H/HeN mouse ileum showing vacant attachment sites, f, Host gene expression in the ileal lamina intestinal in conventional or germ-free mice colonized with either SFB or E. coli for 21 days.
  • TC7, CMT93, and HeLa cells were cultured in DMEM (Gibco 31885) with 10% inactivated fetal calf serum (FCS; AbCys CVFSVF00-0U) and non-essential amino acids (Invitrogen 11140-035).
  • FCS inactivated fetal calf serum
  • mICcl2 were maintained in DMEM F12 advanced medium (Gibco 12634) with 2% inactivated FCS and Glutamax (Gibco 35050) and supplemented with 10 nM hEGF (Sigma E9644), 50 nM dexamethasone (Sigma D4902) and 1 nM triiodothyronine (Sigma T5516).
  • HeLa cells were obtained from ATCC.
  • SFB medium was made up as follows: DMEM/F12 advanced medium with 2% FCS, Glutamax and 12.5 mM HEPES (Sigma H0887) with the following supplementation: 1 in 100 dilution of (1) brain-heart infusion (BD Difco 237500) 5x concentrated, (2) peptone/yeast (BBL Biosafe 211862) at 10% and casein amino acids at 5% (DIFCO 0320-01- 1), (3) ribose/cellobiose/mannose (Sigma: R9629, C7252, M6020) at 200 mM; 1 in 1,000 dilution of (1) ferrous sulphate (Merck 3965) at 10 mM, (2) ferric ammonium citrate (LabGuard 0658) at 12.5 mM, (3) Hemin (Sigma 51280) at 1.5 mM in 50% ethanol with 1.4 N NH40H, (4) sodium ascorbate at 10 mg mf 1 with 1-phosphoascorbate at 500 mM (Sigma
  • SFB medium specific medium supplements except for the nucleotides and hemin were prepared fresh every 2 weeks and otherwise stored at 4 or -20 °C for retinoic acid, and nucleotides.
  • SFB medium was further supplemented with hEGF, dexamethasone, and triiodothyronine.
  • additional supplementation with 0.2% yeast extract BD 212750; 1/100 from 20%
  • yeast extract BD 212750; 1/100 from 20%
  • the filtrate was spun at 8,000g for 5 min to pellet bacteria and insoluble material, and the pellet was resuspended in 3 ml PBS per mouse killed, layered onto 3 ml 50% and 2 ml 30% Nycodenz (AbCYS 1002424) solution made with PBS in 15 ml Falcon tubes and spun for 10 min at 4,000g. SFB within the 30% fraction were collected, diluted in PBS, and bacteria were pelleted for 10 min at 8,500g. Pellets were resuspended in 15 ml pre- equilibrated PBS by pipetting/vortexing and filtered through a 5- ⁇ filter (Sigma Z612502).
  • the filtrate was again centrifuged for 5 min at 8,000g and the pellet was resuspended in an appropriate amount of pre-equilibrated culture medium. Usually one mouse was killed for every four 12-well plates used, and 50 ⁇ of bacterial suspension was added to each well. To facilitate adhesion, cells challenged with SFB were sealed in ziplock bags within the cabinets, removed from the cabinet, and spun for 10 min at 300g.
  • SFB are allowed to grow in the presence of eukaryotic cells for 3 days during which the oxygen concentration is increased incrementally from 1% on day 0 to 1.5% on day 1, to 2% on day 2, and to 2.5% on day 3.
  • Subcultures can be prepared on day 3 by taking aliquots of the culture supernatant and using this to challenge freshly prepared eukaryotic cells (prepared as described above on transwell filters and at low oxygen conditions).
  • the culture supernatant was collected and centrifuged for 4 min at 8,000g and the pellet was resuspended in 100 ⁇ PBS, of which 20 ⁇ was spotted on glass slides for the Gram stain, 30 ⁇ was mixed with an equal volume of 50% glycerol and frozen at -80 °C, and the remaining 50 ⁇ was used for DNA extraction.
  • the DNA was isolated with a Qiagen stool kit (51504; without the use of the inhibitor tablet) and diluted 1 in 20.
  • SFB growth was enumerated by qPCR analysis of the 16S rRNA genes using the following primer pairs: the SFB specific F: 5 ' - AGG AGG AGTCTGCGGC AC ATT AGC-3 ' (SEQ ID NO: 1); and the universal R: 5'-TCCCCACTGCTGCCTCCCGTAG-3' (SEQ ID NO: 2).
  • SFB specific F 5 ' - AGG AGG AGTCTGCGGC AC ATT AGC-3 '
  • R 5'-TCCCCACTGCTGCCTCCCGTAG-3'
  • 6 ⁇ of diluted SFB DNA was mixed with 1.5 ⁇ of a 4 mM primer mix and 7.5 ⁇ of Power SybrGreen Master mix (Applied 4368708) and run on an ABI 7900HT machine in a 384-well plate.
  • SFB segment length analysis used ImageJ.
  • SFB- containing supematants were washed with PBS and suctioned onto 0.1 - ⁇ filters (Watman 110405) and fixed in 0.1 M cacodylate buffer containing 2.5% glutaraldehyde before being processed.
  • Cells for SEM were fixed in PHEM buffer (18.14 g PIPES, 6.5 g HEPES, 3.8 g EGTA, 0.99 g MgS04 per litre with 10 M KOH to pH 7.0) containing 4% sucrose and 2.5% glutaraldehyde, and processed for SEM.
  • PHEM buffer 18.14 g PIPES, 6.5 g HEPES, 3.8 g EGTA, 0.99 g MgS04 per litre with 10 M KOH to pH 7.0
  • glutaraldehyde 4% sucrose and 2.5% glutaraldehyde
  • cells were fixed in PBS/3.7% PFA, permeabilized with PBS/0.1% Triton X-100, stained with DAPI and A568-phalloidin, and stacks of 0.4- ⁇ slices were taken on a Leica SP5 confocal microscope.
  • LPL Lamina limbal growth factor
  • LPL were then purified on a 40-80% Percoll gradient run for 15 min at 2,000g and resuspended in DMEMGlutamax with 8% FCS, 1 mM HEPES, 0.02 mM folic acid, 0.67 mM L-arginine, and 0.27 mM L-asparagine (all from Sigma).
  • LPL for surface antigens and intracellular expression of IL-17 and IL-10 was by flow cytometry as described5. Briefly, LPL were stimulated for 4 h with 100 ng ml -1 phorbol 12-myristate 13 -acetate and 1 ⁇ g ml "1 ionomycin, in the presence of Brefeldin A (10 ⁇ g mF 1 ) (all from Sigma). Cells used for surface analysis were left unstimulated.
  • LPL were labelled for 20 min at 4 °C with a cocktail of the following antibodies: FITC-anti-GL7 (clone GL7), PerCP-anti-CD8a (clone 53-6.7), APC-H7-anti CD4 (clone GK1.5), AF647-anti-B220 (clone RA3-6B/2) (all from BD Pharmingen), PE-anti-IgA (Southern Biotech), and eFluor450-anti-CD45 (clone 30-F11) and PECy7-anti-CD3 (clone 145-2C1 1) (both from eBioscience).
  • FITC-anti-GL7 clone GL7
  • PerCP-anti-CD8a clone 53-6.7
  • APC-H7-anti CD4 clone GK1.5
  • AF647-anti-B220 clone RA3-6B/2
  • PE-anti-IgA Southern Biotech
  • cytokine staining For intracellular cytokine staining, cells were further fixed in 2% PFA for 20 min at room temperature ( -24 °C), and washed and stained overnight at 4 °C with PE-anti-IL-17 (clone TC11-18H10) and APC-anti-IL-10 (clone JES5-16E3) (BD Pharmingen) diluted in PBS-1% FCS-0.5% saponin (Sigma). Labelled cells were analysed with a FACSCanto II and FACSDiva software (BD Biosciences). Gates were set on living cells after Aqua live/dead dye exclusion (Invitrogen).
  • mice For qPCR analysis, the median value of germ-free mice was calculated and used as the reference value of 1 for comparison of the median value of the test samples.
  • Germ-free male and female C3H/HeN mice were obtained from INRA (ANAXEM platform) germ-free facilities. Eight- to nine-week-old germ-free mice were gavaged with 0.5 ml of either fresh anaerobic cultures of E. coli MG1655 or faecal homogenate from SFBmonoassociated mice (Ivanov et al, 2009). Colonization by SFB was monitored in faeces through bacterial DNA extraction and 16S rDNA amplification by qPCR using specific primer pairs for SFB. Values were normalized to Ccl25, a constitutively expressed epithelial cell marker, and compared with the median value from germ-free control mice.
  • Germ-free and gnotobiotic mice were maintained in plastic isolators and fed ad libitum on a commercial diet sterilized by ⁇ -irradiation (40 kGy). The numbers of animals used followed availability of animals, isolators, and were obtained from two independent experiments. Randomization or blinding was otherwise not performed. Gnotobiotic mice were killed on day 21 after colonization in parallel with age-matched germ-free controls. All animal procedures were performed in accordance with French legislation and EEC regulations for the care and use of laboratory animals, approved by the local ethics committee and authorized by the French Ministry of Research.
  • Host response to SFB and MAMPs included pooled results from four independent experiments with three technical samples. Generally a minimum of triplicate biological replicates were used and increased if trends were clear but significance not. After 3 days of in vitro growth of SFB on either mICcl2 or TC7 cells on transwells in SFB medium lacking hemin and sodium ascorbate, at 1-2.5% oxygen, cells were lysed and RNA was extracted using a Nucleospin RNA kit (Macherey-Nagel).
  • cDNA was synthesized using RNA superscript II, oligo dT, RNaseout, and dNTPs (Invitrogen), and pPCR was performed on an ABI 7900HT and QuantStudio7 (Life Technologies) qPCR machine using the protocol described by Schnupf et al, 2012. TaqMan assays were performed as suggested by the supplier. Values were normalized to B2M and Ct values for Reg3y, Tnfa, and Fabp2 were set to 41 in control cells owing to the lack of transcript detection.
  • MAMP stimulation used the following agonists at the highest concentrations recommended by the supplier (Invivogen): Pam2CSK4 (tlrlpm2 s-1) at 100 ng mf 1 , Pam3CSK4 (tlrl-pms) at 300 ng ml "1 , peptidoglycan of E. coli K12 (Tlr-ksspgn) at 10 ⁇ g ml -1 , MDP (tlrl-mdp) at 10 ⁇ g ml "1 , CpG (tlr-1584) at 3 ⁇ g ml -1 , flagellin (tlrl-pstfla-5) at 100 ng mF 1 . Excess for flagellin (10x) was also tested and found to be similar.
  • B2M F:tcagtcgtcagcatggctcgc (SEQ ID NO: 3); R:tccggtgggtggcgtgagtatac (SEQ ID NO: 4) iNos: Fxagctgggctgtacaaacctt (SEQ ID NO: 5); Rxattggaagtgaagcgtttcg (SEQ ID NO: 6) Saal : F.xatttgttcacgaggctttcc (SEQ ID NO: 7); R:gttttccagttagcttccttcatgt (SEQ ID NO: 8) Saa2: F:tgtatcccacaaggtttcaga (SEQ ID NO: 9); R:ttattaccctctctctcaagca (SEQ ID NO: 10)
  • SFB strain Bolotin et al, 2014 isolated from monoassociated mice was deposited at CNCM (Collection Nationale de Cultures de Microorganismes, 25 rue du Do Budapest Roux, Paris) on December 23, 2014, under the accession number CNCM 1-4932 Arthromitus muris strain referred to as SFB-mouse-NL).
  • SFB were cultured with eukaryotic cells grown in low but physiological oxygen conditions (He et al, 1999) in a rich tissue culture medium containing bacterial medium components and additional supplements.
  • SFB growth had a striking dependence on host cell number, decreasing in number with decreasing cell density (Fig. le).
  • negligible growth occurred in medium alone, medium supplemented with cell lysate, or when cells were fixed before SFB challenge (Fig. If), indicating that live host cells are required for SFB proliferation.
  • SFB also required close contact for efficient growth as only little growth (0-6%) occurred when intracellular offspring were added to the bottom chamber of transwells or when bacteria were placed in transwells above TC7 cells in tissue culture wells (Fig. If, g). Yet, as host cell contact was not an absolute requirement, it suggests that host cells may release a soluble factor that promotes SFB growth.
  • SFB were grown on TC7 cells in complete medium or medium missing individual additives.
  • the large primary filament segments start to undergo a symmetrical division to form smaller secondary segments. These differentiate by dividing asymmetrically to form a mother/daughter cell. The daughter cell becomes engulfed and subsequently divides to form two intracellular offspring within the surrounding mother cell segment. Intracellular offspring are then released from the filament by breakdown of the filament septa and cell wall and reattach to the host.
  • FIG. 2D In time-course analysis at this higher oxygen concentration (Fig. 2D), only short bacteria were detected 1 day after challenge (Fig. 2E, F). After 2 days, only long filaments were present (Fig. 2E, F) and the bacterial septa could be identified quite clearly using the Gram stain (Fig. 2F).
  • Three types of filament were found (Fig. 2F, G): short filaments with long intracellular segments of -2.6 ⁇ ; medium-sized filaments with smaller intracellular segments of ⁇ 1.2 ⁇ ; and medium to long filaments that had a more heterogeneous distribution of segment lengths including very small segments (Fig. 2F, G) and rare segments with half-circular structures (Fig.
  • SFB grown in vitro retained their ability to colonize mice and stimulate the characteristic innate and acquired immune responses
  • SFB grown in vitro for 3 days were divided into a filament/intracellular offspring fraction and a pure intracellular offspring fraction (Fig. 5a, b) and gavaged into germ-free mice. Colonization was firmly established by both inputs at 5 days after gavage (Fig. 5c) despite a 140-fold input difference for the filament/intracellular offspring and intracellular offspring fractions.
  • mice gavaged with SFB derived from faecal samples which generally showed good colonization of the ileum
  • mice gavaged with in vzYrogrown SFB (SFBVitro) had much lower numbers of SFB colonizing the ileum (Fig. 3d and Extended Data Fig. Id); instead they showed heavy colonization of the caecum (Fig. 5d).
  • SFBVitro clearly can attach to the ileum
  • these results suggest that ileal colonization may be more efficient by intracellular offspring released from spores found in the faecal input, possibly because of the expression of flagella at this particular stage of the life cycle (Pamp et al., 2012).
  • Fig. 3e the magnitude of the innate host response was proportional to the colonization level of the ileum (Fig. 3e) and not the overall SFB faecal load (Extended Data Fig. lc), revealing the requirement for ileal attachment of SFB to induce the innate host response. Similar to SFBVivo, albeit with less potency, SFB Vitro were also able to stimulate the B-cell compartment in Peyer's patches (Fig. 3f, g), enhance IgA secretion in the faeces (Fig. 3h), and increase the number of Thl7 cells and the level of IL-17A messenger RNA in the small intestine laminalitis (Fig. 3i-k).
  • SFB growth leads to a strong inflammatory host response, with the induction of pleiotropic inflammatory mediators such as tumour-necrosis factor-a (TNF-a), interleukin-l-a (ILl-a), and serum amyloid A 1-3 (Saal-3), induction of several innate host defence mechanisms (Reg3y, iNos, and lactoferrin), and an immunological environment that is conducive for the recruitment of B cells, the transmigration of IgA, recruitment and activation of T cells, and recruitment of neutrophils, dendritic cells, as well as monocytes.
  • TNF-a tumour-necrosis factor-a
  • ILl-a interleukin-l-a
  • Saal-3 serum amyloid A 1-3
  • Reg3y, iNos, and lactoferrin innate host defence mechanisms
  • EXAMPLE 2 METHODS FOR GENETICALLY MODIFYING A SFB STRAIN
  • a series of modular shuttle vectors designed for use in Clostridia species are tested for their ability to be stably introduced into SFB during in vitro growth using both conjugation and transformation.
  • Each plasmid contains a different origin of replication with a choice of antibiotic resistance cassettes, multiple cloning sites and promoters. Conjugation and transformation are performed during in vitro growth of SFB.
  • An auxotrophic E. coli strain requiring the addition of Diaminopimelic acid to the medium for growth is used as a donor strain as this strain can be easily selected against in rich medium with the absence of diaminopimelic acid.
  • SFB strain is purified from monoassociated mice as described above and intracellular offsprings (IOs) are added to host cells (TC7 cells) grown on either tissue culture or transwell plates under conditions described for SFB growth above.
  • IOs intracellular offsprings
  • diaminopimelic acid 100 ug/ml
  • the donor E. coli strain requiring dap addition for growth and carrying a plasmid
  • a given time e.g. 4-8 hours
  • in vitro grown (cultured) SFB are collected and mixed with the aforementioned E.coli strain and pelleted (all under low oxygen) and maintained in a pellet for varying amounts of time (e.g., 4-8 hours).
  • Bacteria are collected and washed 2x with regular SFB growth medium lacking diaminopimelic acid before being put on fresh eukaryotic cells (always at low oxygen) with regular SFB medium but complemented with the appropriate antibiotic to which the conjugal plasmid gives SFB resistance to.
  • SFV are collected and gavaged into germfree mice.
  • Recombinant SFB are selected for and maintained by antibiotic treatment of the drinking water.
  • the optimal and minimal regime of antibiotic use in the drinking water that is needed to cure SFB monoassociated mice from SFB is determined prior and used to select for recombinant SFB.
  • SFB are grown (cultured) in vitro for 2-4 days on TC7 cells.
  • SFB are collected and put on ice. Under low oxygen conditions and working with solutions put on ice, SFB are washed 6x with 10% glycerol/pre-equilibrated water before being resuspended and concentrated with 10% glycerol/H20.
  • Purified plasmid DNA is added and SFB is electroporated (6.5 kV.cm- 1 to 25kV.cm-').
  • SFB are placed in regular SFB medium again and spun onto fresh cells. SFB are allowed to recover for 3-24 hours before selective antibiotic be added overnight.
  • SFB are gavaged into GF mice.
  • Recombinant SFB are selected for and maintained by antibiotic treatment of the drinking water. Transformation by the chemical method: calcium chloride and heat shock
  • SFB are grown in vitro for 2-4 days on TC7 cells.
  • SFB are collected and put on ice. Under low oxygen conditions and working with solutions put on ice, SFB are washed 5x with 0.1M calcium chloride before being resuspended and concentrated with 10% glycerol/0.1M calcium chloride.
  • Purified plasmid DNA is added to SFB and incubated for 30 minutes.
  • SFB are heat shocked at 42°C for 30 seconds before being placed in regular SFB medium again and spun onto fresh cells. SFB are allowed to recover for 3-24 hours before selective antibiotic be added overnight.
  • SFB are gavaged into GF mice.
  • the above procedure may be performed at room temperature only without heat shock.
  • Recombinant SFB are selected for and maintained by antibiotic treatment of the drinking water.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/IB2014/067285 2014-12-23 2014-12-23 Method of culturing segmented filamentous bacteria in vitro Ceased WO2016103005A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PCT/IB2014/067285 WO2016103005A1 (en) 2014-12-23 2014-12-23 Method of culturing segmented filamentous bacteria in vitro
CN201580072958.4A CN107429222B (zh) 2014-12-23 2015-12-23 在体外培养分节丝状菌的方法
AU2015370419A AU2015370419B2 (en) 2014-12-23 2015-12-23 Method of culturing segmented filamentous bacteria in vitro
CA2971933A CA2971933C (en) 2014-12-23 2015-12-23 Method of culturing segmented filamentous bacteria in vitro
JP2017534355A JP6963999B2 (ja) 2014-12-23 2015-12-23 セグメント細菌のインビトロ培養法
EP15830866.8A EP3237602B1 (en) 2014-12-23 2015-12-23 Method of culturing segmented filamentous bacteria in vitro
PCT/IB2015/059948 WO2016103217A1 (en) 2014-12-23 2015-12-23 Method of culturing segmented filamentous bacteria in vitro
US15/538,184 US10435665B2 (en) 2014-12-23 2015-12-23 Method of culturing segmented filamentous bacteria in vitro
US16/548,280 US11725183B2 (en) 2014-12-23 2019-08-22 Method of culturing segmented filamentous bacteria in vitro

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2014/067285 WO2016103005A1 (en) 2014-12-23 2014-12-23 Method of culturing segmented filamentous bacteria in vitro

Publications (1)

Publication Number Publication Date
WO2016103005A1 true WO2016103005A1 (en) 2016-06-30

Family

ID=52462962

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2014/067285 Ceased WO2016103005A1 (en) 2014-12-23 2014-12-23 Method of culturing segmented filamentous bacteria in vitro
PCT/IB2015/059948 Ceased WO2016103217A1 (en) 2014-12-23 2015-12-23 Method of culturing segmented filamentous bacteria in vitro

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/059948 Ceased WO2016103217A1 (en) 2014-12-23 2015-12-23 Method of culturing segmented filamentous bacteria in vitro

Country Status (6)

Country Link
US (2) US10435665B2 (cg-RX-API-DMAC7.html)
EP (1) EP3237602B1 (cg-RX-API-DMAC7.html)
JP (1) JP6963999B2 (cg-RX-API-DMAC7.html)
CN (1) CN107429222B (cg-RX-API-DMAC7.html)
AU (1) AU2015370419B2 (cg-RX-API-DMAC7.html)
WO (2) WO2016103005A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016103005A1 (en) * 2014-12-23 2016-06-30 Institut Pasteur Method of culturing segmented filamentous bacteria in vitro
CN106011281B (zh) * 2016-07-19 2019-04-23 浙江大学 肠道分节丝状菌鞭毛蛋白的检测方法
DE102018213030A1 (de) * 2018-08-03 2020-02-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien
WO2021155229A1 (en) * 2020-01-31 2021-08-05 Iowa State University Research Foundation, Inc. Gut bacterium-based treatment to increase poultry gut health and food safety
CA3218163A1 (en) 2021-05-17 2022-11-24 Anne PALERMO Food product comprising a co-culture of bacteria and fungi
WO2026011048A1 (en) * 2024-07-03 2026-01-08 Ohio State Innovation Foundation Commensal bacterial antigen as a therapeutic agent for cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011046616A2 (en) * 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
WO2014121298A2 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Methods of populating a gastrointestinal tract

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2556835B1 (en) * 2010-02-10 2015-08-05 Japan Eco-Science Co. Ltd. Mixture, dissolving solution and pharmaceutical agent each comprising thermophilic microorganism
WO2016103005A1 (en) * 2014-12-23 2016-06-30 Institut Pasteur Method of culturing segmented filamentous bacteria in vitro

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011046616A2 (en) * 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
WO2014121298A2 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Methods of populating a gastrointestinal tract

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
BOLOTIN, A ET AL., GENOME ANNOUNC., vol. 2, 2014, pages 1 - 2
CHAPPERT, P. ET AL., IMMUNITY, vol. 38, 2013, pages 1198 - 1210
CHASE, D.G.; ERLANDSEN, S.L., J. BACTERIOL., vol. 127, 1976, pages 572 - 583
DANCHIN A., MOLEC. GEN. GENET., vol. 150, 1977, pages 293 - 299
DAVIS, C.P.; SAVAGE, D.C., INFECTION AND IMMUNITY, vol. 13, 1976, pages 180 - 188
E. J. STEWART: "Growing Unculturable Bacteria", JOURNAL OF BACTERIOLOGY, vol. 194, no. 16, 1 June 2012 (2012-06-01), pages 4151 - 4160, XP055198147, ISSN: 0021-9193, DOI: 10.1128/JB.00345-12 *
ERICSSON, A.C. ET AL., COMPARATIVE MEDICINE, vol. 64, 2014, pages 90 - 98
FERGUSON, D.J.; BIRCH-ANDERSEN, A., ACTA PATHOL. MICROBIOL. SCAND. B, vol. 87, 1979, pages 247 - 252
GABORIAU-ROUTHIAU, V. ET AL., IMMUNITY, vol. 31, 2009, pages 677 - 689
GODON, J.J. ET AL., APPL. ENVIRON. MICROBIOL., vol. 63, 1997, pages 2802 - 2813
GOTO, Y. ET AL., SCIENCE, vol. 345, 2014, pages 1254009
HE, G. ET AL., PROC. NATL ACAD. SCI. USA, vol. 96, 1999, pages 4586 - 4591
HEAP, J.T. ET AL., J. MICROBIOL. METHODS, vol. 78, 2009, pages 79 - 85
IVANOV, I.I. ET AL., CELL, vol. 139, 2009, pages 485 - 498
JEPSON, M.A. ET AL., INFECT. IMMUN., vol. 61, 1993, pages 4001 - 4004
KLAASEN, H. ET AL., FEMS MICROBIOL., vol. 88, 1992, pages 165 - 180
KRIEGEL, M.A. ET AL., PROC. NATL ACAD. SCI. USA, vol. 108, 2011, pages 11548 - 11553
KUWAHARA, T. ET AL., DNA RES., vol. 18, 2011, pages 291 - 03
LÉCUYER, E. ET AL., IMMUNITY, vol. 40, 2014, pages 608 - 620
LEE, Y.K., PROC. NATL ACAD. SCI. USA, vol. 108, no. 1, 2011, pages 4615 - 4622
MITSUTOSHI SENOH ET AL: "Conversion of viable but nonculturable enteric bacteria? to culturable by co-culture with eukaryotic cells", MICROBIOLOGY AND IMMUNOLOGY, vol. 56, no. 5, 27 April 2012 (2012-04-27), pages 342 - 345, XP055198160, ISSN: 0385-5600, DOI: 10.1111/j.1348-0421.2012.00440.x *
PAMP, S.J. ET AL., GENOME RES., vol. 22, 2012, pages 1107 - 1119
PRAKASH, T. ET AL., CELL HOST MICROBE, vol. 10, 2011, pages 273 - 284
S. J. PAMP ET AL: "Single-cell sequencing provides clues about the host interactions of segmented filamentous bacteria (SFB)", GENOME RESEARCH, vol. 22, no. 6, 20 March 2012 (2012-03-20), pages 1107 - 1119, XP055198149, ISSN: 1088-9051, DOI: 10.1101/gr.131482.111 *
SCHNUPF, P. ET AL., SEMIN. IMMUNOL., vol. 25, 2013, pages 342 - 351
SCHNUPF, P.; SANSONETTI, P.J., PLOS ONE, vol. 7, 2012, pages E36446
SCZESNAK, A. ET AL., CELL HOST MICROBE, vol. 10, 2011, pages 260 - 272
SHIMA, T. ET AL., FEMS IMMUNOL. MED MICROBIOL., vol. 52, 2008, pages 69 - 77
TANNOCK, G.W. ET AL., APPL. ENVIRON. MICROBIOL., vol. 47, 1984, pages 441 - 442
WU, H.J. ET AL., IMMUNITY, vol. 32, 2010, pages 815 - 827
YIN, Y. ET AL., ISME J., vol. 7, 2012, pages 615 - 621
YURKOVETSKIY, L. ET AL., IMMUNITY, vol. 39, 2013, pages 400 - 412

Also Published As

Publication number Publication date
JP6963999B2 (ja) 2021-11-10
JP2018505666A (ja) 2018-03-01
US20170335276A1 (en) 2017-11-23
EP3237602B1 (en) 2020-06-10
AU2015370419B2 (en) 2021-12-23
WO2016103217A1 (en) 2016-06-30
EP3237602A1 (en) 2017-11-01
US20190367867A1 (en) 2019-12-05
CN107429222B (zh) 2021-06-15
CA2971933A1 (en) 2016-06-30
US11725183B2 (en) 2023-08-15
AU2015370419A1 (en) 2017-08-03
CN107429222A (zh) 2017-12-01
US10435665B2 (en) 2019-10-08

Similar Documents

Publication Publication Date Title
US11725183B2 (en) Method of culturing segmented filamentous bacteria in vitro
US11826424B2 (en) Compositions and methods for induction of Th17 cells
Schnupf et al. Growth and host interaction of mouse segmented filamentous bacteria in vitro
Roselli et al. The novel porcine Lactobacillus sobrius strain protects intestinal cells from enterotoxigenic Escherichia coli K88 infection and prevents membrane barrier damage
CN108676774B (zh) 诱导调节性t细胞的增殖或积累的人源细菌
KR101473058B1 (ko) 과민성 대장 증후군 예방 또는 치료용 조성물
EP2238238B1 (en) Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
EP3493823B1 (en) Postbiotic-based composition for treatment of ocular inflammation
Chen et al. Immunogenicity and protective efficacy of the Mycobacterium avium subsp. paratuberculosis attenuated mutants against challenge in a mouse model
US20150216932A1 (en) Probiotic bacteria as carrier for a helminth-derived immunomodulator for the treatment of inflammatory disorders
Shen et al. In vitro immunomodulatory effects of thymol and cinnamaldehyde in a pig intestinal epithelial cell line (IPEC-J2)
Hudcovic et al. Priority order of neonatal colonization by a probiotic or pathogenic Escherichia coli strain dictates the host response to experimental colitis
CA2971933C (en) Method of culturing segmented filamentous bacteria in vitro
Loos et al. Genetically engineered Lactococcus lactis secreting murine IL‐10 modulates the functions of bone marrow‐derived dendritic cells in the presence of LPS
Benada et al. Priority order of neonatal colonization by a probiotic or pathogenic Escherichia coli strain
CN118086354A (zh) 一种表达人溶菌酶的布拉迪酵母系统及其构建方法和应用
CN116479031A (zh) 一种利用布拉迪酵母表达四环素降解酶Tet(X)的方法与应用
HK1234318B (en) Compositions and methods for induction of th17 cells
HK1234318A1 (en) Compositions and methods for induction of th17 cells
HK1261280B (en) Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14835582

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14835582

Country of ref document: EP

Kind code of ref document: A1